|
|
|
|
 Dr Liliane Goetsch,
Head of Experimental Oncology Department Institute de Recherche Pierre Fabre PhD in Cellular Biology (1991), Lecturer in Cellular Biology at the University Claude Bernard of Lyon (1986), Research fellowship at the Centre Léon Bérard of Lyon (1987-1991), Research scientist at the Laboratoire Aguettant of Lyon (1090-1991), L. Goetsch joined the Department of Cellular Biology at the Centre d’Immunologie Pierre Fabre (CIPF) in 1992 as a Research Scientist. She created in 1994 of the hybridoma group to generate novel antibody tools for immunological studies. In parallel she was involved in evaluating and studying the mechanisms of action of a RSV vaccine developed at the CIPF. She then worked (1997-2002) on the discovery of carrier proteins targeting dendritic cells to improve both humoral and cellular responses against weak immunogens. In 1998 L. Goetsch started working on humanised antibodies as project manager and suggested IGF-1 receptor as a target for such compounds. This activity led to the discovery of an anti-IGF-1R humanised antibody (h7C10/MK0646) with in vitro and in vivo anti-tumoral activities that have been licensed to Merck and Co. and that is currently evaluated in clinical trials. Since 2004 L. Goetsch is serving as Head of Experimental Cancer Research Department at the CIPF and her team is in charge of the generation and selection of new therapeutic humanised antibodies to be used in the cancer field. They recently discovered a bivalent humanized therapeutic antibody against c-Met that is able to block both ligand-dependent and ligand-independent c-Met driven tumours. This antibody described as hz224G11 is currently developed in partnership with Abbott.Appearing: DAY 2 WEDNESDAY 22 SEPTEMBER – IMPROVING PRE-CLINICAL & EARLY DEVELOPMENT 4.10pm Case study: targeting c-met receptor with a novel monoclonal antibody
- What was the rationale behind approaching c-met inhibition with a monoclonal antibody?
- What were the challenges encountered in developing h224G11 to target a TKR?
- How were these problems overcome, and what is the clinical outlook for developing h224G11 into a viable treatment for cancer?
Dr Liliane Goetsch, Head of Experimental Oncology Department,
Institute de Recherche Pierre Fabre 4.40pm Expert Q&A panel discussion: are we aiming at a moving target?
- Different approaches to targeted therapy: is the target actually the driving force?
- What are the implications for therapies which have an effect in patients without a particular target? Does this interrupt that targeted cancer therapy paradigm?
- Understanding strategies and solutions to improve targets for cancer therapy.
Senior Vice President Oncology,
Merck Serono Dr Liliane Goetsch, Head of Experimental Oncology Department,
Institute de Recherche Pierre Fabre Chief Technology Officer,
Silicon Biosystems Senior Group Leader,
Friedrich Miescher Institute for Biomedical Research (Part of the Novartis Research Foundation) |
|
|
|
|
Conference:
Day 1
September 21, 8:30am - 5:30pm
Day 2
September 22, 8:30am - 5:30pm
Day 3
September 23, 9am - 5:30pm
|
|
|
|
|
|
|
|
|
